Ingredient comparison

Exenatide vs Orforglipron

Last updated

Compare the ingredients, then check the specific brand, formulation, and dose. Approved uses and prices vary by product.

Exenatide vs Orforglipron: lowest prices now

Every cash quote was checked on or after .Data feeds · Nov 16, 2026 UTC
Exenatide vs Orforglipron: overview
CompareExenatideOrforglipron
What it is for

FDA-approved for

  • Type 2 diabetes

FDA-approved for

  • Weight loss
Brands
Foundayo

Small-molecule GLP-1

Route & frequency

Subcutaneous injection

Twice daily (Byetta); once weekly (Bydureon BCise)

Oral tablet (any time of day, no food or water restriction)

Once daily

FDA shortage report

National reporting does not confirm stock at your pharmacy.

Coverage & source records

National reporting does not confirm stock at your pharmacy.

Coverage & source records
What was tested together

Direct comparative evidence

No direct comparative trial is included for these ingredients in our reviewed catalog. The separate trial results below do not establish which works better.

Product-specific self-pay

What the quoted price covers

Lowest tracked quotes for FDA-approved products, selected separately for each price basis. Entry prices may refer to different brands or formulations. Supply periods, eligibility, refill deadlines, and additional fees can change what you pay.

Exenatide vs Orforglipron: sourced cash quotes
CompareExenatideOrforglipron
Advertised entry price
~$422 per pen (goodrx.com/exenatide)

Generic exenatide (Amneal)

GoodRx

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Third-party reported price

Days of supply not on record; not ranked per 30 days.

Checked on goodrx.com

Price conditions

GoodRx coupon, lowest listed price for one 5 mcg pen (60 doses: 30 days at the twice-daily dose)

Every exenatide product is now discontinued: the FDA withdrew the Byetta and Bydureon approvals in 2025, and Amneal's generic is listed by the FDA as discontinued too. Pharmacies may still dispense remaining stock.

$149/30 days (pharmacy.amazon.com/FOUNDAYO-0-8-MG-TABLET-Bottle-30-Tablet/dp/B0GVPY57CT)

Foundayo via Amazon Pharmacy

Amazon Pharmacy

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

30-day supply (pharmacy.amazon.com)

$149 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, 0.8 mg; includes the manufacturer coupon if eligible (list price $648.90); prescription required

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

At the named trial dose

No sourced quote tracked for this price basis.

$299/30 days (pharmacy.amazon.com/Eli-Lilly-FOUNDAYO-17-2-MG-TABLET-Bottle-30-Tablet/dp/B0GVPWWC4K)

Foundayo via Amazon Pharmacy

At 17.2 mg

Amazon Pharmacy

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90)

30-day supply (pharmacy.amazon.com)

$299 per 30 days at this quoted rate

Offer through

Checked on pharmacy.amazon.com

Price conditions

without insurance, with Lilly's self-pay card, which ends 12/31/2026 and requires each refill within 45 days of the previous delivery, as Lilly's Foundayo savings page states (otherwise Lilly's regular $349); 17.2 mg; includes the manufacturer coupon if eligible (list price $648.90)

Amazon fills a prescription you already have and delivers in all 50 states. FDA-approved product.

30-day supply

Every offerSee the offerAll 51 offers

USD self-pay, not insurance or pharmacy acquisition cost. A trial dose is not a personal dosing recommendation. Compounded offers are shown separately in the offer browser and are not FDA-approved.

Separate studies

Trial outcomes in context

Each result belongs to its own trial, population, dose, and analysis. Weight loss, HbA1c change, and adverse events may come from different studies even within one ingredient. These are study averages, not predictions of your result.

Exenatide vs Orforglipron: individual trial outcomes
CompareExenatideOrforglipron
Weight change
≈−4% (diabetesjournals.org/care/article/33/6/1255/27340/DURATION-1-Exenatide-Once-Weekly-Produces) (-4.1 kg (~4% of the 102 kg baseline) at 52 wks · DURATION-1 · 2 mg weekly (Bydureon))

-4.1 kg (~4% of the 102 kg baseline) at 52 wks

DURATION-1 (diabetesjournals.org)

2 mg weekly (Bydureon)

Approximation from kilograms; see trial methods

Study context

The oldest GLP-1; a diabetes trial with a modest weight effect.

−11.2% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (-11.2% at 72 wks · ATTAIN-1 · 17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose))

-11.2% at 72 wks

ATTAIN-1 (nejm.org)

17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)

Accounts for treatment discontinuation

Study context

The first oral small-molecule GLP-1 pill for weight loss (Foundayo, FDA-approved April 2026): pill convenience with injectable-class efficacy. -11.2% is the primary (treatment-regimen) endpoint; the efficacy estimand was -12.4%.

HbA1c change (percentage points)
−1.9 pp (pubmed.ncbi.nlm.nih.gov/18782641) (-1.9% at 30 wks · DURATION-1 · HbA1c change in percentage points)

-1.9 percentage points at 30 wks

DURATION-1 (pubmed.ncbi.nlm.nih.gov)
−1.5 pp (investor.lilly.com/node/52521) (-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1) · ACHIEVE-1 · HbA1c change in percentage points)

-1.5 percentage points at 40 wks (36 mg, ACHIEVE-1)

ACHIEVE-1 (investor.lilly.com)
Adverse events

Stopped treatment for adverse events

3.9% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (3.9% discontinued for adverse reactions · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Reported nausea

8.2% (accessdata.fda.gov/drugsatfda_docs/label/2024/209210s024lbl.pdf) (Nausea in the drug arm · Bydureon BCise FDA label (2 mg, type 2 diabetes))

Bydureon BCise FDA label (2 mg, type 2 diabetes)

from the FDA label adverse-reactions table (DURATION-1 does not cleanly report AE discontinuation); a diabetes population

Stopped treatment for adverse events

10.3% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (10.3% vs 2.7% placebo (36 mg) · ATTAIN-1 (36 mg, 72 wks, obesity))

Reported nausea

33.7% (nejm.org/doi/abs/10.1056/NEJMoa2511774) (Nausea in the drug arm · ATTAIN-1 (36 mg, 72 wks, obesity))

ATTAIN-1 (36 mg, 72 wks, obesity)

From FDA and CMS records

Timing, generics and coverage

Read from each FDA label, FDA's Orange Book and CMS's Part D files, and updated when they change.

BrandSoonest top doseHalf-lifeGeneric approved?Patent on the medicine to
Foundayo17.2 mg from day 151about 29 to 49 hoursNoSep 26, 2037

How long each takes · Generics and patents · Who covers what

Check the product label

Approved uses & full records

Exenatide

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

381 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record

Orforglipron

Indications depend on the brand and formulation. Read the product-specific indications and prescribing information in the full record.

53 registered ingredient studies (clinicaltrials.gov/search). Count checked . Research activity, not a measure of evidence quality.

Open full record
Reading the comparison

Common questions

Is Exenatide or Orforglipron better for weight loss?

No trial on our list compared them directly. In separate trials: Exenatide -4.1 kg (~4% of the 102 kg baseline) at 52 wks in DURATION-1 (2 mg weekly (Bydureon)) (diabetesjournals.org); Orforglipron -11.2% at 72 wks in ATTAIN-1 (17.2 mg daily (Foundayo; the label's equivalent of ATTAIN-1's 36 mg dose)) (nejm.org). Separate trials enrolled different people for different lengths of time, so these figures cannot rank them.

Is Exenatide or Orforglipron safer?

We know of no trial set up to answer that. Stopping because of side effects, each in its own trial and not a head-to-head figure: Exenatide 3.9% discontinued for adverse reactions (Bydureon BCise FDA label (2 mg, type 2 diabetes)) (accessdata.fda.gov); Orforglipron 10.3% vs 2.7% placebo (36 mg) (ATTAIN-1 (36 mg, 72 wks, obesity)) (nejm.org). Each FDA label lists its own warnings, and which ones matter depends on your health.

What Orforglipron dose is equivalent to Exenatide?

No FDA label sets a dose of Exenatide that equals a dose of Orforglipron, and we know of no trial that defines one. Switching is a prescriber's decision, and each label sets its own starting dose and steps.

Which costs less: Exenatide or Orforglipron?

Compare the named products and price conditions below. A tracked entry quote can be a different brand or formulation from the product studied in a trial. A trial-dose quote applies only to the named product and dose; neither figure is an estimate of your whole treatment cost or an insurance quote.

Do these trial results tell me which medication is best?

Direct trials compare the treatments, doses, and participants they studied. Results from separate trials differ in population, duration, dose, and analysis, so their percentages do not establish a treatment ranking. Discuss your medical history and the specific product label with a licensed clinician.

Does FDA shortage status mean my pharmacy has stock?

No. FDA shortage records describe national supply reports and covered presentations, not inventory at an individual pharmacy. Unknown status means the data cannot establish a current assessment. Confirm local stock with your pharmacy.

Updated automatically

What changed for Exenatide and Orforglipron

  • PriceSingleCare: Foundayo tablets (SingleCare coupon) now ranked per 30 days at about $601: ~$601 per 30 tablets buys 30 days (dailymed.nlm.nih.gov/dailymed/drugInfo.cfm)
  • PriceGoodRx: Generic exenatide (Amneal) now ~$422 per pen (was ~$447 per pen) (read on goodrx.com)
  • RecallRecall: Exenatide Injection, USP, 250 mcg/mL, 1.2 mL per prefilled pen (api.fda.gov/drug/enforcement.json)
  • FDAFDA approved a labeling supplement for Foundayo (accessdata.fda.gov/scripts/cder/daf/index.cfm)
  • FDA labelFDA label updated: Foundayo (Eli Lilly and Company), effective 2026-07-29 (api.fda.gov/drug/label.json)
  • FDA labelFDA label updated: Exenatide (Amneal Pharmaceuticals LLC), effective 2026-05-27 (api.fda.gov/drug/label.json)

Written from each source's own record as it changes. Every change on GLPcompare

Automated feed checks do not constitute a clinical or editorial review. Sources & methodology

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.